Analysts expect Redhill Biopharma Ltd. (NASDAQ:RDHL) to announce $340,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Redhill Biopharma’s earnings. The lowest sales estimate is $170,000.00 and the highest is $500,000.00. The firm is scheduled to issue its next quarterly earnings results on Tuesday, July 25th.

On average, analysts expect that Redhill Biopharma will report full-year sales of $340,000.00 for the current financial year, with estimates ranging from $1.12 million to $3.75 million. For the next fiscal year, analysts anticipate that the business will report sales of $45.54 million per share, with estimates ranging from $11.01 million to $113.90 million. Zacks’ sales averages are an average based on a survey of research firms that cover Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) last posted its earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.50) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.64) by $0.14.

A number of brokerages have recently issued reports on RDHL. FBR & Co restated a “buy” rating on shares of Redhill Biopharma in a research report on Wednesday, April 5th. HC Wainwright set a $33.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a research report on Thursday, May 4th. Roth Capital set a $26.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a research report on Thursday, May 4th. Finally, Zacks Investment Research upgraded shares of Redhill Biopharma from a “hold” rating to a “buy” rating and set a $9.75 price target on the stock in a research report on Tuesday, July 4th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RDHL. Oppenheimer & Co. Inc. increased its position in Redhill Biopharma by 36.5% in the first quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock worth $221,000 after buying an additional 6,172 shares during the last quarter. Penserra Capital Management LLC increased its position in Redhill Biopharma by 75.0% in the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock worth $171,000 after buying an additional 7,647 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Redhill Biopharma during the first quarter worth about $101,000. Family Management Corp bought a new position in Redhill Biopharma during the first quarter worth about $163,000. Finally, Renaissance Technologies LLC bought a new position in Redhill Biopharma during the fourth quarter worth about $266,000. Institutional investors own 12.31% of the company’s stock.

Redhill Biopharma (NASDAQ RDHL) traded up 1.99% during mid-day trading on Friday, reaching $8.70. 21,087 shares of the company were exchanged. The stock’s market capitalization is $147.96 million. The company’s 50 day moving average price is $9.43 and its 200-day moving average price is $9.89. Redhill Biopharma has a 12-month low of $8.20 and a 12-month high of $16.54.

COPYRIGHT VIOLATION WARNING: “$340,000.00 in Sales Expected for Redhill Biopharma Ltd. (RDHL) This Quarter” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/14/340000-00-in-sales-expected-for-redhill-biopharma-ltd-rdhl-this-quarter-2.html.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Get a free copy of the Zacks research report on Redhill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.